Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (603392.SS)
- Previous Close
63.40 - Open
63.00 - Bid 68.26 x --
- Ask 68.27 x --
- Day's Range
63.00 - 69.74 - 52 Week Range
40.14 - 88.00 - Volume
11,101,456 - Avg. Volume
10,493,023 - Market Cap (intraday)
86.568B - Beta (5Y Monthly) --
- PE Ratio (TTM)
68.95 - EPS (TTM)
0.99 - Earnings Date --
- Forward Dividend & Yield 1.00 (1.46%)
- Ex-Dividend Date Jun 5, 2023
- 1y Target Est
69.43
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. researches, develops, produces, distributes, and sells infectious disease diagnostic reagents and vaccines in China and internationally. The company provides COVID 19, HIV and HTLV, Hepatitis, EV-71, and Tuberculosis diagnostics test kits; Hepatitis C and Syphilis detection reagents; automated immunoassays; ELISA kits and rapid tests for infectious disease diagnostics; chemiluminescence and clinical chemistry reagents; immunodiagnostic reagents; and Hepatitis E and human papillomavirus vaccines. It serves blood banks, hospitals and clinics, reference laboratories, border inspection centers, blood-processing companies, and research institutes. The company was founded in 1991 and is headquartered in Beijing, China.
www.ystwt.comRelated News
Performance Overview: 603392.SS
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 603392.SS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 603392.SS
Valuation Measures
Market Cap
86.57B
Enterprise Value
81.00B
Trailing P/E
68.95
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
15.61
Price/Book (mrq)
6.82
Enterprise Value/Revenue
14.70
Enterprise Value/EBITDA
49.64
Financial Highlights
Profitability and Income Statement
Profit Margin
3.80%
Return on Assets (ttm)
-0.04%
Return on Equity (ttm)
0.92%
Revenue (ttm)
3.38B
Net Income Avi to Common (ttm)
128.47M
Diluted EPS (ttm)
0.99
Balance Sheet and Cash Flow
Total Cash (mrq)
5.83B
Total Debt/Equity (mrq)
2.55%
Levered Free Cash Flow (ttm)
658.97M
Research Analysis: 603392.SS
Company Insights: 603392.SS
603392.SS does not have Company Insights